Figure 7. CD61 status predicts the overall survival of the cancer patients.

(A) The levels of CD61 expression in human lung cancer tissues were determined by mmunohistochemistry staining of the lung cancer tissues in tissue microarray with the anti-CD61 antibody. The lung cancers were stratified into CD61^high and CD61^low lung cancers based on the strength of CD61 staining on tissue array slides that contain 100 human lung cancer samples. Lower panels display the magnification of the original images in a different field. (B) Kaplan-Meier survival probability of the lung cancer patients based on the CD61 status in the lung cancer tissues. (C) Relapse-free survival probability of the breast cancer patients based on the expression of the CD61 gene. (D) Overall survival probability of the ovarian cancer patients based on the expression of the CD61 gene.